Argenx is pursuing label extension for Vyvgart, including through two Phase 3 studies for seronegative gMG (ADAPT-SERON) and ocular MG (ADAPT-OCULUS). UNLOCKED: 5 NEW TRADES EVERY WEEK.

Richard J. Nowak, MD, MS, Yale School of Medicine, explains what some early myasthenia gravis symptoms are and their impact on research efforts.

In fact, the majority of people with an MG diagnosis first notice symptoms in their eyes. A 2019 prospective cohort study examining eye weakness in MG found that 82% of participants had eye ...

argenx also highlighted its commitment to reach the broader MG patient community with two ongoing label expansion studies in ocular myasthenia gravis (oMG) and seronegative MG (snMG). In addition, ...